

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

ARBUTUS BIOPHARMA CORPORATION	)	
and GENEVANT SCIENCES GmbH,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 22-252 (JDW)
	)	
MODERNA, INC. and MODERNATX, INC.	)	
	)	
Defendants.	)	
MODERNA, INC. and MODERNATX, INC.,	)	
	)	
Counterclaim-Plaintiffs,	)	
	)	
v.	)	
	)	
ARBUTUS BIOPHARMA CORPORATION	)	
and GENEVANT SCIENCES GmbH,	)	
	)	
Counterclaim-Defendants.	)	

**PLAINTIFFS' UNOPPOSED MOTION TO  
SEAL PORTIONS OF *DAUBERT* BRIEFING**

Pursuant to the Protective Order (D.I. 91) as modified by the Court's November 14, 2023 Order (D.I. 155), and the Court's July 28, 2025 Order (D.I. 503), Plaintiffs respectfully move this Court to seal their sensitive and confidential information and to grant leave to file partially redacted versions of the following documents:

1. Plaintiffs' Nov. 7, 2025, Opening Brief in Support of Motion to Exclude Expert Testimony;
2. Moderna's Nov. 7, 2025, Opposition to Plaintiffs' Motion to Exclude Expert Testimony;

3. Plaintiffs' Nov. 21, 2025, Reply Brief in Support of Motion to Exclude Expert Testimony;
4. Moderna's Nov. 21, 2025, Memorandum in Support of Moderna's *Daubert* Motion;
5. Plaintiffs' Dec. 5, 2025, Opposition Brief to Moderna's *Daubert* Motion;
6. Moderna's Dec. 5, 2025, Reply Brief in support of Moderna's *Daubert* Motion;
7. Exhibit 1
8. Exhibit 3
9. Exhibit 5
10. Exhibit 13
11. Exhibit 14
12. Exhibit 31
13. Exhibit 36
14. Exhibit 33
15. Exhibit 37
16. Exhibit 38
17. Exhibit A
18. Exhibit C
19. Exhibit D
20. Exhibit R
21. Exhibit S
22. Exhibit V

Plaintiffs seek leave to file under seal Exhibit 12.

The parties' motion, supporting papers, and the exhibits thereto, redact for Plaintiffs' confidential information. The grounds for this motion are set forth in Plaintiffs' brief in support

of this motion, together with the declaration of Pete Zorn, attached as Exhibit A. Pursuant to Section I.D.2 of the Court's Policies and Procedures, highlighting has been applied to the sealed version of the documents identified above.

Pursuant to D. Del. LR 7.1.1, counsel certifies that the parties met and conferred, and Moderna does not oppose this motion.

Plaintiffs respectfully request that the Court grant their motion and enter the enclosed order granting leave to file redacted versions of the documents identified above.

OF COUNSEL:

David I. Berl  
Adam D. Harber  
Thomas S. Fletcher  
Shaun P. Mahaffy  
Andrew L. Hoffman  
Matthew W. Lachman  
Ricardo Leyva  
Arthur J. Argall III  
Falicia Elenberg  
Kathryn Larkin  
WILLIAMS & CONNOLLY LLP  
680 Maine Avenue S.W.  
Washington, DC 20024  
(202) 434-5000

Andrei Iancu  
Jeffrey B. Wall  
Sullivan & Cromwell llp  
1700 New York Avenue, N.W.  
Suite 700  
Washington, DC 20006  
(202) 956-7500  
*Attorneys for Genevant  
Sciences GmbH*

Daralyn J. Durie  
Adam R. Brausa  
Eric C. Wiener  
Annie A. Lee  
Shaelyn K. Dawson  
MORRISON & FOERSTER LLP  
425 Market Street  
San Francisco, CA 94105-2482  
(415) 268-6080  
Kira A. Davis  
MORRISON & FOERSTER LLP  
707 Wilshire Boulevard  
Los Angeles, CA 90017-3543  
(213) 892-5200

/s/ Nathan R. Hoeschen

John W. Shaw (No. 3362)  
Karen E. Keller (No. 4489)  
Nathan R. Hoeschen (No. 6232)  
SHAW KELLER LLP  
I.M. Pei Building  
1105 North Market Street, 12th Floor  
Wilmington, DE 19801  
(302) 298-0700  
jshaw@shawkeller.com  
kkeller@shawkeller.com  
nhoeschen@shawkeller.com  
*Attorneys for Plaintiffs/Counterclaim-  
Defendants*

David N. Tan  
MORRISON & FOERSTER LLP  
2100 L Street, NW, Suite 900  
Washington, DC 20037  
(202) 887-1500  
*Attorneys for Arbutus  
Biopharma Corporation*

Dated: December 16, 2025